Factor H inhibits complement activation induced by liposomal and micellar drugs and the therapeutic antibody rituximab in vitro

Adkinson, 2002, Task force report: future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions, J Allergy Clin Immunol, 109, S461, 10.1067/mai.2002.122214 Demoly, 1999, Predictive capacity of histamine release for the diagnosis of drug allergy, Allergy, 54, 500, 10.1034/j.1398-9995.1999.00020.x Szebeni, 2014, Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals, Mol Immunol, 61, 163, 10.1016/j.molimm.2014.06.038 Lasser, 1979, Complement and contrast material reactors, J Allergy Clin Immunol, 64, 105, 10.1016/0091-6749(79)90043-5 Lenz, 2007, Management and preparedness for infusion and hypersensitivity reactions, Oncologist, 12, 601, 10.1634/theoncologist.12-5-601 Cheifetz, 2005, Monoclonal antibodies, immunogenicity, and associated infusion reactions, Mt Sinai J Med, 72, 250 Szebeni, 2001, Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents, Crit Rev Ther Drug Carrier Syst, 18, 567, 10.1615/CritRevTherDrugCarrierSyst.v18.i6.50 Ricklin, 2010, Complement: a key system for immune surveillance and homeostasis, Nat Immunol, 11, 785, 10.1038/ni.1923 Rodríguez de Córdoba, 2004, The human complement factor H: functional roles, genetic variations and disease associations, Mol Immunol, 41, 355, 10.1016/j.molimm.2004.02.005 Ferreira, 2010, Complement control protein factor H: the good, the bad, and the inadequate, Mol Immunol, 47, 2187, 10.1016/j.molimm.2010.05.007 Kopp, 2012, Factor H: a complement regulator in health and disease, and a mediator of cellular interactions, Biomolecules, 2, 46, 10.3390/biom2010046 Szebeni, 1998, Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study, J Natl Cancer Inst, 90, 300, 10.1093/jnci/90.4.300 Szebeni, 2012, Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and Am Bisome, Nanomedicine, 8, 176, 10.1016/j.nano.2011.06.003 Castiblanco-Valencia, 2012, Leptospiral immunoglobulin-like proteins interact with human complement regulators factor H, FHL-1, FHR-1, and C4BP, J Infect Dis, 205, 995, 10.1093/infdis/jir875 Hebecker, 2013, An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H, J Immunol, 191, 912, 10.4049/jimmunol.1300269 van den Hoven, 2013, Complement activation by PEGylated liposomes containing prednisolone, Eur J Pharm Sci, 49, 265, 10.1016/j.ejps.2013.03.007 Józsi, 2002, Complement receptor type 1 (CD35) mediates inhibitory signals in human B lymphocytes, J Immunol, 168, 2782, 10.4049/jimmunol.168.6.2782 Wu, 2009, Structure of complement fragment C3b-factor H and implications for host protection by complement regulators, Nat Immunol, 10, 728, 10.1038/ni.1755 Józsi, 2007, The C-terminus of complement factor H is essential for host cell protection, Mol Immunol, 44, 2697, 10.1016/j.molimm.2006.12.001 Kajander, 2011, Dual interaction of factor H with C3d and glycosaminoglycans in host–nonhost discrimination by complement, Proc Natl Acad Sci U S A, 108, 2897, 10.1073/pnas.1017087108 Morgan, 2011, Structural basis for engagement by complement factor H of C3b on a self surface, Nat Struct Mol Biol, 18, 463, 10.1038/nsmb.2018 Heinen, 2009, Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation, Blood, 114, 2439, 10.1182/blood-2009-02-205641 Timmann, 1991, Two major serum components antigenically related to complement factor H are different glycosylation forms of a single protein with no factor H-like complement regulatory functions, J Immunol, 146, 1265, 10.4049/jimmunol.146.4.1265 Szebeni, 1999, Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody, Circulation, 99, 2302, 10.1161/01.CIR.99.17.2302 Smith, 2001, Membrane-targeted complement inhibitors, Mol Immunol, 38, 249, 10.1016/S0161-5890(01)00047-5 Smith, 2002, Targeting anticomplement agents, Biochem Soc Trans, 30, 1037, 10.1042/bst0301037 Ricklin, 2013, Complement in immune and inflammatory disorders: therapeutic interventions, J Immunol, 190, 3839, 10.4049/jimmunol.1203200 Kishore, 2012, Factor H as a regulator of the classical pathway activation, Immunobiology, 217, 162, 10.1016/j.imbio.2011.07.024 Kuznetsova, 2014, Differential binding of plasma proteins by liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the bilayer, Biochemistry (Mosc), 79, 797, 10.1134/S0006297914080070 Schmidt, 2013, Rational engineering of a minimized immune inhibitor with unique triple-targeting properties, J Immunol, 190, 5712, 10.4049/jimmunol.1203548 Nichols, 2015, An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy, Kidney Int, 88, 1314, 10.1038/ki.2015.233 Strobel, 2011, Factor H-related protein 1 neutralizes anti-factor H autoantibodies in autoimmune hemolytic uremic syndrome, Kidney Int, 80, 397, 10.1038/ki.2011.152 Goicoechea de Jorge, 2013, Dimerization of complement factor H-related proteins modulates complement activation in vivo, Proc Natl Acad Sci U S A, 110, 4685, 10.1073/pnas.1219260110 Tortajada, 2013, C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation, J Clin Invest, 123, 2434, 10.1172/JCI68280 Józsi, 2015, Factor H-related proteins determine complement-activating surfaces, Trends Immunol, 36, 374, 10.1016/j.it.2015.04.008 Baldo, 2013, Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses, Oncoimmunology, 2, e26333, 10.4161/onci.26333 Kimby, 2005, Tolerability and safety of rituximab (MabThera), Cancer Treat Rev, 31, 456, 10.1016/j.ctrv.2005.05.007 Boross, 2012, Mechanisms of action of CD20 antibodies, Am J Cancer Res, 2, 676 Hörl, 2013, Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity, Leukemia, 27, 2200, 10.1038/leu.2013.169 Hakobyan, 2010, Variant-specific quantification of factor H in plasma identifies null alleles associated with atypical hemolytic uremic syndrome, Kidney Int, 78, 782, 10.1038/ki.2010.275 Harris, 2012, The complotype: dictating risk for inflammation and infection, Trends Immunol, 33, 513, 10.1016/j.it.2012.06.001 Kozma, 2015, Variable association of complement activation by rituximab and paclitaxel in cancer patients in vivo and in their screening serum in vitro with clinical manifestations of hypersensitivity: a pilot study, Eur J Nanomed, 7, 289, 10.1515/ejnm-2015-0026 Fülöp, 2015, The possible role of factor H in complement activation-related pseudoallergy (CARPA): a failed attempt to correlate blood levels of FH with liposome-induced hypersensitivity reactions in patients with autoimmune disease, Eur J Nanomed, 7, 7, 10.1515/ejnm-2015-0004